~" Twenty-five patients with tumors of the central nervous system received bromodeoxyuridine (BUdR), 200 mg/sq m, by intravenous infusion every 8 hours for 3 days before surgery. Excised tumor specimens were fixed in chilled 70% ethanol, embedded in paraffin, and cut into 6-um sections. Each section was reacted with monoclonal antibodies against BUdR and stained with immunoperoxidase to identify nuclei that had incorporated BUdR. The growth fraction of each tumor was estimated by calculating the ratio of BUdRpositive nuclei to the total number of tumor cells in three to six microscopic fields in viable areas of the tumor. In seven cases, the tumor doubling time was measured from the serial computerized tomography scans and an attempt was made to estimate the cell cycle time.
S
EVERAL investigators have used autoradiography to determine the labeling index (LI) or S-phase fraction of human brain tumors exposed to a pulse of tritiated (3H)-thymidine.3 '5,8'9 .~2.~4, 24 However, in order to understand the growth of individual brain tumors in situ, knowledge of the cell cycle time and growth fraction of each tumor is essential.~~ Unfortunately, the techniques developed in the past to estimate these parameters require sequential biopsies, which are considered unethical in patients with brain tumors. Alternative methods for estimating the growth fraction and cell cycle time involve the use of 3H-thymidine, which is radioactive and inherently hazardous, and autoradiography, which is very time-consuming; therefore, these methods have been used in only a limited number of patients with brain tumors. 9A~ The present study was designed to determine the growth fraction and cell cycle time of various brain tumors exposed in situ to bromodeoxyuridine (BUdR), a nonradioactive thymidine analogue. The results of cell kinetics studies performed with BUdR are available within days after biopsy, and the information obtained can be used to predict prognosis and to select chemotherapeutic regimens in individual patients.
Clinical Material and Methods
Patients with tumors of the central nervous system who were scheduled for biopsy or surgical resection of their lesions were recruited for this study. Informed consent was obtained from each patient.
All patients received a 30-minute intravenous infusion of BUdR, 200 mg/sq m, every 8 hours for 3 days before craniotomy. A portion of each surgical specimen was placed in chilled 70% ethanol, fixed for at least 12 hours, and embedded in paraffin. Sections were cut 6 um thick, deparaffinized with xylene, and processed immunohistochemically as previously described. 17 Briefly, the tissue sections were denatured for 1 hour in 2N HC1, covered with 1:30 dilution of purified antiBUdR monoclonal antibody* in phosphate-buffered saline containing 0.5% Tween 20, and left at room temperature for 45 minutes. Next, the slides were reacted with a 1:200 dilution of peroxidase-conjugated anti-mouse immunoglobulin (It) G antibodyt in phosphate-buffered saline for 45 minutes at room temperature and then with 0.025% diaminobenzidine tetrahydrochloride and 0.003% H202 in Tris-hydrochloride buffer for 10 to 15 minutes. Finally, the slides were lightly counterstained with 10% Gill hematoxylin. The remaining portion of each excised tumor specimen was fixed in 10% formalin or in 2.5% glutaraldehyde solution for routine histological examination.
The growth fraction was estimated by counting the number of cells in three to six microscopic fields in histologically viable areas; 1000 to 2000 cells were counted in each tumor. The growth fraction was expressed as the ratio of BUdR-labeled cells to the total number of cells counted.
In seven patients, the growth rate of the tumor was determined by calculating the tumor doubling time (Td) from the equation Td = t log 2/log (Vt/Vo), where Vo indicates the initial tumor volume and Vt the volume at time "t. ''26 The volume of the tumor was estimated from serial contrast-enhanced computerized tomography (CT) scans. On all CT slices, enhanced or lowdensity regions were outlined with a tablet digitizer, and their areas were calculated with a minicomputer system. All enhanced or low-density areas were separately multiplied by the slice thickness and were added to obtain the volume of the tumor.
We also attempted to calculate the cell cycle time (Tc) of the tumors in these seven patients. Assuming that there is no cell loss during the interval between volume measurements, the cell cycle time can be derived from the equation Tc = t log (1 + GF)/log (Vt/ Vo), where GF is the growth fraction. 1~
Results
The clinical data for the 25 patients who entered the study and the growth fractions of their tumors are summarized in Table 1 . The time from the onset of initial neurological signs to operation ranged from 0.7 to 78 months. In the six patients who had recurrent tumors, the time from relapse to operation ranged from 1 to 37 months. In the 14 patients with glioblastoma, astrocytoma, or metastatic tumor, the interval ranged from 1 to 9 months, which was shorter than that in * Anti-BUdR monoclonal antibody obtained from BectonDickinson, Mountain View, California.
1" Peroxidase-conjugated anti-mouse immunoglobulin G antibody obtained from Cappel Laboratories, Inc., Malvern, Pennsylvania. patients with histologically benign tumors such as meningiomas, neurinomas, and adenomas.
The average growth fractions of glioblastoma multiforme and malignant glioma ranged from 9.1% to 46.5 %, whereas low-grade gliomas showed growth fractions of 2.0% and 6.7%. One medulloblastoma (Case 14) revealed mostly astrocytic differentiation and had a growth fraction of 9.3%. The growth fractions of metastatic brain tumors ranged from 11.2% to 43.2% and those of pituitary adenomas were 0.8% and 1.9%. Acoustic neurinomas and meningiomas had growth fractions between 3.9% and 8.2%. There was no appreciable difference in the growth fractions of recurrent and primary tumors.
The tumor growth rates (determined from serial CT scans) and the calculated cell cycle times for seven patients are shown in Table 2 . The longest tumor doubling time (842 days) was in a patient with an acoustic neurinoma (Case 22). The doubling times for malignant gliomas and the metastatic tumors were considerably shorter. Little relationship was observed between tumor doubling times and growth fractions. Similarly, the cell cycle time did not correlate with the growth fraction or with the malignancy of each tumor. However, in the majority of cases, the cell cycle times ranged from 5 to 12 days (Table 2) .
Discussion
Since the concept of a cell cycle was introduced by Howard and Pelc in 1953, ~ many investigators have sought to determine the cell kinetics of normally and abnormally proliferating tissues in vivo and in vitro. The synthesis of 3H-thymidine in the mid-1950's led to the development of many sophisticated approaches to define the rate and pattern of cellular proliferation. 2 The first cell kinetics study of a human brain tumor in situ was performed in 1960 by Johnson, et al. 12 Other investigators later used in vitro study techniques. 3'~4 However, because complete cell kinetics studies of human brain tumors are very difficult and time-consuming to perform, and are complicated as well by ethical considerations, most of these studies have been limited to obtaining the so-called "labeling index" (LI). The LI represents the proportion of tumor cells engaged in deoxyribonucleic acid (DNA) synthesis (S phase) in preparation for mitosis, and can be obtained by autoradiography of tumor tissue that has been exposed to a pulse of 3H-thymidine. 22 Cell kinetics studies with 3H-thymidine have shown that histopathologically malignant gliomas, such as glioblastoma multiforme, medulloblastoma, and malignant astrocytoma, have LI's of 5% to 15%, while most low-grade or well-differentiated gliomas had LI's of less than 1%. 5'8-10'14'24 Hoshino and Wilson 9 reported that the LI of a tumor correlated closely with the prognosis or survival of the patient. Thus, the LI reflects the proliferative activity of the tissue being studied. However, although a high LI indicates an actively proliferating tissue, equal LI's do not necessarily indicate equal proliferative activity. The actual rate of proliferation of a tumor depends not only on the proportion of cells in the S phase but also on the growth fraction, the cell cycle time, and the rate of cell loss from the tumor cell population.
Cell loss is a growth-limiting factor and therefore may be viewed as a favorable event. Although it is clearly evident as focal or massive tumor necrosis, cell loss is very difficult to quantitate. Therefore, determination of the growth fraction and the cell cycle time is critical to understanding the actual growth potential of a tumor. Because of the difficulty of determining these variables autoradiographically, few attempts have been made to measure the growth fraction and the cell cycle time of various gliomas. 9'1~ Nevertheless, it appears that the rate of tumor growth depends more on the growth fraction than on the cell cycle time. Thus, the higher rate of tumor growth indicated by a higher LI seems to be the result of a higher growth fraction. 9
The growth fraction was first defined mathematically by Mendelsohn, ~5 who introduced the method of calculation into cell population kinetics, as the number of proliferating cells divided by the total cell population. Other methods of calculating this variable experimentally were later developed, but not all of them provide conclusive results or are applicable for the study of tumors in humans. Continuous exposure of a cell pop-ulation to 3H-thymidine for a period lasting at least as long as the cell cycle time is one way to approximate the growth fraction. 22 All cycling cells will pass through the S phase during that period and will incorporate 3H-thymidine. Cells that fail to incorporate the thymidine are considered non-cycling (or Go) cells. As might be expected, for obvious reasons studies involving continuous or fractionated injections of 3H-thymidine proved extremely difficult to perform and were hazardous to the patient. However, this technique is more feasible when BUdR is used instead of 3H,thymidine.
The development of a monoclonal antibody that detects BUdR-labeled nuclei 7 was a breakthrough for cell kinetics studies on human tumors in situ. Like 3H-thymidine, BUdR is taken up by cells in S phase and can be used in place of 3H-thymidine. This antibody and newly developed antibodies identify BUdR specifically; 4"25 in our experience, no reaction product has been observed in tumor tissues that were not exposed to BUdR. Cells labeled with BUdR can be readily identified by immunofluorescent or immunoperoxidase stains. 4'7'17'~8 Although mutagenic or teratogenic effects have occurred with high doses or prolonged administration of BUdR, 6 the dose required for cell kinetics studies (150 to 200 mg/sq m) ~7 is virtually nontoxic, in contrast to the dose used therapeutically as a radiosensitizing agent. ~'13'16'19'2~ Because BUdR is not radioactive, it can be used with fewer restrictions than 3H-thymidine to investigate the cell kinetics of human tumors in situ.
The dosing schedule used in the present study was selected because in many brain tumors the expected duration of the S phase is 7 to 10 hours 8,24 and the cell cycle time is 2 to 3 days. 9'1~
We therefore administered BUdR, 200 mg/sq m, in a 30-minute intravenous infusion every 8 hours for 3 days before scheduled tumor biopsy in patients with various types of brain tumor. The growth fractions determined by this method were very high for malignant gliomas, including glioblastoma multiforme (range 9% to 46%) and metastatic brain tumors (ll% to 43%), and low for low-grade astrocytoma (2% to 7%), meningioma (3.9% to 8.2%), neurinoma (3.9% and 4.1%), and pituitary adenoma (0.8% and 1.9%). These results confirm that the fastergrowing tumors contain a larger population of proliferating cells. In addition, the growth fractions of malignant gliomas in this study are quite similar to those reported by Tym 24 and by Hoshino and Wilson, 9 who used a different method to estimate the growth fraction in gliomas.
We are not certain whether differences in the growth fraction help us to predict more accurately the grade of malignancy in individual tumors. Careful monitoring of the cases in the present study should in the near future demonstrate to what extent the actual rate of tumor growth is reflected in the growth fraction. Nevertheless, because it indicates not only proliferative potential but also the percentage of the tumor cell population that is vulnerable to cell cycle specific Y. Yoshii, et al.
agents, the growth fraction is a more valuable measure than the LI. 9 Even though the growth fractions determined in this study appeared to correlate well with the proliferative potential of the tumors as reflected by their clinical behavior, they did not correlate with the doubling times calculated in seven cases. The cell cycle times in these cases were calculated assuming no cell loss; however, it is more likely that cell loss was substantial, 2~ and therefore the actual cell cycle time would be far shorter than the 5 to 12 days estimated for the majority of these tumors. In fact, this substantial cell loss may account for the inconsistency of the tumor doubling times in those cases. Most of the malignant tumors were treated by radiation therapy or chemotherapy, which undoubtedly affected their growth, and would therefore affect the tumor volume determined from serial CT scans. Thus, the cell cycle times in this study may be considerably overestimated and should be interpreted with caution.
Even though the growth fraction and cell cycle times estimated by our method are still ambiguous, they nevertheless provide useful information about the proliferative potential of individual tumors. The development of more sophisticated techniques using BUdR to determine the growth fraction and cell cycle time may allow us to estimate these variables with greater accuracy in the future.
